Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis

NCT00613171 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Sclerosis, Scleroderma

Interventions

DRUG: STI571

Sponsor

Novartis Pharmaceuticals